Surge in demand for hormonal therapy and phototherapy to treat the new born and children by lowering the bilirubin levels in propelling the market growth
Surge in demand for hormonal therapy and phototherapy to treat the new born and children by lowering the bilirubin levels in propelling the market growth
Fact.MR, Rockville MD: An ongoing market study by Fact.MR on global erythropoietic protoporphyria (EPP) treatment, evaluates a moderate growth for the upcoming decade. Owing to the technical advancements in the diagnostics and treatment of EPP.
According to Fact.MR, increasing demand for drug therapies such as antihistamine, hormonal therapy, phototherapy for EPP treatment to boost the demand through 2021 and beyond. Rising cases of erythropoietic protoporphyria in children is fueling the growth. First line hormonal therapies segment is expected to hold major market share until 2031.
For instance, according to a study by WHO, cases of porphyria were recorded approximately 5 cases per 100,000 person, among which majority of them were diagnosed in children. The prevalence for erythropoietic protoporphyria is recorded among 2% of the patients diagnosed with porphyria, for which the most common treatment is hormonal therapy approved by FDA.
“Significant demand of advanced EPP treatment therapeutics for EPP treatment and rising cases of enzyme deficiency among children is propelling the growth,” says the Fact.MR analyst.
Request a report sample to gain comprehensive insights at https://www.factmr.com/connectus/sample?flag=S&rep_id=4717
Key Takeaways
- US to remain in the spotlight owing to the emergence of novel treatment advancements
- Germany likely to emerge as the second most lucrative market owing to the rising cases of porphyria and treatment adoption
- China expected to lead the East Asia with the highest growth rate
- Owing to the poor healthcare infrastructure, GCC and rest of MEA expected to witness sluggish growth
- Hormonal therapy is likely to emerge as one of the most lucrative segment through 2021
- Retail and Hospital pharmacies is anticipated to emerge as highly sought after erythropoietic protoporphyria (EPP) treatment availability channel
Prominent Drivers
- Increasing cases of porphyria in children is surging the demand of antihistamines therapy to propel the growth
- Novel therapeutic development and technical advancement is driving the growth of EPP treatment market
Key Restraints
- Higher treatment cost and lack of healthcare facilities is posing a threat to the growth
Discover more about erythropoietic protoporphyria (EPP) treatment market with figures, data tables and the table of contents. You will also find detailed market segmentation on https://www.factmr.com/report/4717/erythropoietic-protoporphyria-epp-treatment-market
Competitive Landscape
Key PCR master mix manufacturers profiled by Fact.MR include Clinuvel Pharmaceuticals ALS, Johnson & Johnson, Tishcon Corp., Fenton Pharmaceuticals Ltd., In-Life Co., L’Oreal S.A, Pfizer Inc., Teva Pharmaceuticals, Sun Pharma Ltd., and Mylan N.V. others among others. As evaluated by Fact.MR, manufacturers are focusing on developing new model in order to sustain and recover after the pandemic outbreak.
In 2020, a clinical trial was conducted in collaboration with researchers at Karolinska Institute in Sweden now shows that a new drug candidate can prevent attacks in the patients with acute porphyria.
Also, in March 2020, Alnylam announced approval of GIVLAARI® (givosiran) in the European Union for the treatment of acute hepatic porphyria (AHP) in adults and adolescents.
More Insights on the Erythropoietic Protoporphyria (EPP) Treatment Market
Fact.MR recent study offers an unbiased analysis on global erythropoietic protoporphyria (EPP) treatment market. In order to understand the global market potential, its growth, and opportunities, the market is segmented on the basis of therapy (hormonal therapy, adjunctive therapies, and phototherapy), distribution channels (hospital pharmacies, drug stores, retail pharmacies and online pharmacies), and regions (North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East and Africa)
Request For No-Obligation Table Of Content
https://www.factmr.com/connectus/sample?flag=T&rep_id=4717
Explore Fact.MR’s Coverage on the Healthcare Domain
Phototherapy Devices Market: Latest report by Fact.MR offers an exhaustive analysis on global phototherapy devices market on the opportunities, trends and challenges for the forecast period. The study analyzes crucial trends that are currently determining market growth. This report explicates on vital dynamics, such as the drivers, restraints, and opportunities for key market players along with key stakeholders and emerging players.
Acute Hepatic Porphyria (APH) Market: A detailed assessment of acute hepatic porphyria (APH) value chain analysis, business execution, and supply chain analysis across regional markets has been covered in the report. A list of prominent companies operating in the market along with their product portfolios enhances the reliability of this comprehensive research study.
Hormone Replacement Therapy Market: Fact.MR has published a detailed market insight on the global market for hormone replacement therapy market. A comprehensive estimate on eye socket implant market has been provided through an optimistic scenario as well as a conservative scenario, taking into account the detailed segmentation and exhaustive competitive landscape during the forecast period.
About Fact.MR
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.
Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E: sales@factmr.com
Market Intelligence Services: Marketngage.com
Source: Fact.MR
Erythropoietic Protoporphyria Treatment Reliant on Rising Cases of Porphyria: Study
Surge in demand for hormonal therapy and phototherapy to treat the new born and children by lowering the bilirubin levels in propelling the market growth
Fact.MR, Rockville MD: An ongoing market study by Fact.MR on global erythropoietic protoporphyria (EPP) treatment, evaluates a moderate growth for the upcoming decade. Owing to the technical advancements in the diagnostics and treatment of EPP.
According to Fact.MR, increasing demand for drug therapies such as antihistamine, hormonal therapy, phototherapy for EPP treatment to boost the demand through 2021 and beyond. Rising cases of erythropoietic protoporphyria in children is fueling the growth. First line hormonal therapies segment is expected to hold major market share until 2031.
For instance, according to a study by WHO, cases of porphyria were recorded approximately 5 cases per 100,000 person, among which majority of them were diagnosed in children. The prevalence for erythropoietic protoporphyria is recorded among 2% of the patients diagnosed with porphyria, for which the most common treatment is hormonal therapy approved by FDA.
“Significant demand of advanced EPP treatment therapeutics for EPP treatment and rising cases of enzyme deficiency among children is propelling the growth,” says the Fact.MR analyst.
Request a report sample to gain comprehensive insights at https://www.factmr.com/connectus/sample?flag=S&rep_id=4717
Key Takeaways
- US to remain in the spotlight owing to the emergence of novel treatment advancements
- Germany likely to emerge as the second most lucrative market owing to the rising cases of porphyria and treatment adoption
- China expected to lead the East Asia with the highest growth rate
- Owing to the poor healthcare infrastructure, GCC and rest of MEA expected to witness sluggish growth
- Hormonal therapy is likely to emerge as one of the most lucrative segment through 2021
- Retail and Hospital pharmacies is anticipated to emerge as highly sought after erythropoietic protoporphyria (EPP) treatment availability channel
Prominent Drivers
- Increasing cases of porphyria in children is surging the demand of antihistamines therapy to propel the growth
- Novel therapeutic development and technical advancement is driving the growth of EPP treatment market
Key Restraints
- Higher treatment cost and lack of healthcare facilities is posing a threat to the growth
Discover more about erythropoietic protoporphyria (EPP) treatment market with figures, data tables and the table of contents. You will also find detailed market segmentation on https://www.factmr.com/report/4717/erythropoietic-protoporphyria-epp-treatment-market
Competitive Landscape
Key PCR master mix manufacturers profiled by Fact.MR include Clinuvel Pharmaceuticals ALS, Johnson & Johnson, Tishcon Corp., Fenton Pharmaceuticals Ltd., In-Life Co., L’Oreal S.A, Pfizer Inc., Teva Pharmaceuticals, Sun Pharma Ltd., and Mylan N.V. others among others. As evaluated by Fact.MR, manufacturers are focusing on developing new model in order to sustain and recover after the pandemic outbreak.
In 2020, a clinical trial was conducted in collaboration with researchers at Karolinska Institute in Sweden now shows that a new drug candidate can prevent attacks in the patients with acute porphyria.
Also, in March 2020, Alnylam announced approval of GIVLAARI® (givosiran) in the European Union for the treatment of acute hepatic porphyria (AHP) in adults and adolescents.
More Insights on the Erythropoietic Protoporphyria (EPP) Treatment Market
Fact.MR recent study offers an unbiased analysis on global erythropoietic protoporphyria (EPP) treatment market. In order to understand the global market potential, its growth, and opportunities, the market is segmented on the basis of therapy (hormonal therapy, adjunctive therapies, and phototherapy), distribution channels (hospital pharmacies, drug stores, retail pharmacies and online pharmacies), and regions (North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East and Africa)
Request For No-Obligation Table Of Content
https://www.factmr.com/connectus/sample?flag=T&rep_id=4717
Explore Fact.MR’s Coverage on the Healthcare Domain
Phototherapy Devices Market: Latest report by Fact.MR offers an exhaustive analysis on global phototherapy devices market on the opportunities, trends and challenges for the forecast period. The study analyzes crucial trends that are currently determining market growth. This report explicates on vital dynamics, such as the drivers, restraints, and opportunities for key market players along with key stakeholders and emerging players.
Acute Hepatic Porphyria (APH) Market: A detailed assessment of acute hepatic porphyria (APH) value chain analysis, business execution, and supply chain analysis across regional markets has been covered in the report. A list of prominent companies operating in the market along with their product portfolios enhances the reliability of this comprehensive research study.
Hormone Replacement Therapy Market: Fact.MR has published a detailed market insight on the global market for hormone replacement therapy market. A comprehensive estimate on eye socket implant market has been provided through an optimistic scenario as well as a conservative scenario, taking into account the detailed segmentation and exhaustive competitive landscape during the forecast period.
About Fact.MR
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.
Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E: sales@factmr.com
Market Intelligence Services: Marketngage.com
Source: Fact.MR
Erythropoietic Protoporphyria Treatment Reliant on Rising Cases of Porphyria: Study
Surge in demand for hormonal therapy and phototherapy to treat the new born and children by lowering the bilirubin levels in propelling the market growth
Fact.MR, Rockville MD: An ongoing market study by Fact.MR on global erythropoietic protoporphyria (EPP) treatment, evaluates a moderate growth for the upcoming decade. Owing to the technical advancements in the diagnostics and treatment of EPP.
According to Fact.MR, increasing demand for drug therapies such as antihistamine, hormonal therapy, phototherapy for EPP treatment to boost the demand through 2021 and beyond. Rising cases of erythropoietic protoporphyria in children is fueling the growth. First line hormonal therapies segment is expected to hold major market share until 2031.
For instance, according to a study by WHO, cases of porphyria were recorded approximately 5 cases per 100,000 person, among which majority of them were diagnosed in children. The prevalence for erythropoietic protoporphyria is recorded among 2% of the patients diagnosed with porphyria, for which the most common treatment is hormonal therapy approved by FDA.
“Significant demand of advanced EPP treatment therapeutics for EPP treatment and rising cases of enzyme deficiency among children is propelling the growth,” says the Fact.MR analyst.
Request a report sample to gain comprehensive insights at https://www.factmr.com/connectus/sample?flag=S&rep_id=4717
Key Takeaways
- US to remain in the spotlight owing to the emergence of novel treatment advancements
- Germany likely to emerge as the second most lucrative market owing to the rising cases of porphyria and treatment adoption
- China expected to lead the East Asia with the highest growth rate
- Owing to the poor healthcare infrastructure, GCC and rest of MEA expected to witness sluggish growth
- Hormonal therapy is likely to emerge as one of the most lucrative segment through 2021
- Retail and Hospital pharmacies is anticipated to emerge as highly sought after erythropoietic protoporphyria (EPP) treatment availability channel
Prominent Drivers
- Increasing cases of porphyria in children is surging the demand of antihistamines therapy to propel the growth
- Novel therapeutic development and technical advancement is driving the growth of EPP treatment market
Key Restraints
- Higher treatment cost and lack of healthcare facilities is posing a threat to the growth
Discover more about erythropoietic protoporphyria (EPP) treatment market with figures, data tables and the table of contents. You will also find detailed market segmentation on https://www.factmr.com/report/4717/erythropoietic-protoporphyria-epp-treatment-market
Competitive Landscape
Key PCR master mix manufacturers profiled by Fact.MR include Clinuvel Pharmaceuticals ALS, Johnson & Johnson, Tishcon Corp., Fenton Pharmaceuticals Ltd., In-Life Co., L’Oreal S.A, Pfizer Inc., Teva Pharmaceuticals, Sun Pharma Ltd., and Mylan N.V. others among others. As evaluated by Fact.MR, manufacturers are focusing on developing new model in order to sustain and recover after the pandemic outbreak.
In 2020, a clinical trial was conducted in collaboration with researchers at Karolinska Institute in Sweden now shows that a new drug candidate can prevent attacks in the patients with acute porphyria.
Also, in March 2020, Alnylam announced approval of GIVLAARI® (givosiran) in the European Union for the treatment of acute hepatic porphyria (AHP) in adults and adolescents.
More Insights on the Erythropoietic Protoporphyria (EPP) Treatment Market
Fact.MR recent study offers an unbiased analysis on global erythropoietic protoporphyria (EPP) treatment market. In order to understand the global market potential, its growth, and opportunities, the market is segmented on the basis of therapy (hormonal therapy, adjunctive therapies, and phototherapy), distribution channels (hospital pharmacies, drug stores, retail pharmacies and online pharmacies), and regions (North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East and Africa)
Request For No-Obligation Table Of Content
https://www.factmr.com/connectus/sample?flag=T&rep_id=4717
Explore Fact.MR’s Coverage on the Healthcare Domain
Phototherapy Devices Market: Latest report by Fact.MR offers an exhaustive analysis on global phototherapy devices market on the opportunities, trends and challenges for the forecast period. The study analyzes crucial trends that are currently determining market growth. This report explicates on vital dynamics, such as the drivers, restraints, and opportunities for key market players along with key stakeholders and emerging players.
Acute Hepatic Porphyria (APH) Market: A detailed assessment of acute hepatic porphyria (APH) value chain analysis, business execution, and supply chain analysis across regional markets has been covered in the report. A list of prominent companies operating in the market along with their product portfolios enhances the reliability of this comprehensive research study.
Hormone Replacement Therapy Market: Fact.MR has published a detailed market insight on the global market for hormone replacement therapy market. A comprehensive estimate on eye socket implant market has been provided through an optimistic scenario as well as a conservative scenario, taking into account the detailed segmentation and exhaustive competitive landscape during the forecast period.
About Fact.MR
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.
Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E: sales@factmr.com
Market Intelligence Services: Marketngage.com
Source: Fact.MR
Erythropoietic Protoporphyria Treatment Reliant on Rising Cases of Porphyria: Study
Surge in demand for hormonal therapy and phototherapy to treat the new born and children by lowering the bilirubin levels in propelling the market growth
Fact.MR, Rockville MD: An ongoing market study by Fact.MR on global erythropoietic protoporphyria (EPP) treatment, evaluates a moderate growth for the upcoming decade. Owing to the technical advancements in the diagnostics and treatment of EPP.
According to Fact.MR, increasing demand for drug therapies such as antihistamine, hormonal therapy, phototherapy for EPP treatment to boost the demand through 2021 and beyond. Rising cases of erythropoietic protoporphyria in children is fueling the growth. First line hormonal therapies segment is expected to hold major market share until 2031.
For instance, according to a study by WHO, cases of porphyria were recorded approximately 5 cases per 100,000 person, among which majority of them were diagnosed in children. The prevalence for erythropoietic protoporphyria is recorded among 2% of the patients diagnosed with porphyria, for which the most common treatment is hormonal therapy approved by FDA.
“Significant demand of advanced EPP treatment therapeutics for EPP treatment and rising cases of enzyme deficiency among children is propelling the growth,” says the Fact.MR analyst.
Request a report sample to gain comprehensive insights at https://www.factmr.com/connectus/sample?flag=S&rep_id=4717
Key Takeaways
- US to remain in the spotlight owing to the emergence of novel treatment advancements
- Germany likely to emerge as the second most lucrative market owing to the rising cases of porphyria and treatment adoption
- China expected to lead the East Asia with the highest growth rate
- Owing to the poor healthcare infrastructure, GCC and rest of MEA expected to witness sluggish growth
- Hormonal therapy is likely to emerge as one of the most lucrative segment through 2021
- Retail and Hospital pharmacies is anticipated to emerge as highly sought after erythropoietic protoporphyria (EPP) treatment availability channel
Prominent Drivers
- Increasing cases of porphyria in children is surging the demand of antihistamines therapy to propel the growth
- Novel therapeutic development and technical advancement is driving the growth of EPP treatment market
Key Restraints
- Higher treatment cost and lack of healthcare facilities is posing a threat to the growth
Discover more about erythropoietic protoporphyria (EPP) treatment market with figures, data tables and the table of contents. You will also find detailed market segmentation on https://www.factmr.com/report/4717/erythropoietic-protoporphyria-epp-treatment-market
Competitive Landscape
Key PCR master mix manufacturers profiled by Fact.MR include Clinuvel Pharmaceuticals ALS, Johnson & Johnson, Tishcon Corp., Fenton Pharmaceuticals Ltd., In-Life Co., L’Oreal S.A, Pfizer Inc., Teva Pharmaceuticals, Sun Pharma Ltd., and Mylan N.V. others among others. As evaluated by Fact.MR, manufacturers are focusing on developing new model in order to sustain and recover after the pandemic outbreak.
In 2020, a clinical trial was conducted in collaboration with researchers at Karolinska Institute in Sweden now shows that a new drug candidate can prevent attacks in the patients with acute porphyria.
Also, in March 2020, Alnylam announced approval of GIVLAARI® (givosiran) in the European Union for the treatment of acute hepatic porphyria (AHP) in adults and adolescents.
More Insights on the Erythropoietic Protoporphyria (EPP) Treatment Market
Fact.MR recent study offers an unbiased analysis on global erythropoietic protoporphyria (EPP) treatment market. In order to understand the global market potential, its growth, and opportunities, the market is segmented on the basis of therapy (hormonal therapy, adjunctive therapies, and phototherapy), distribution channels (hospital pharmacies, drug stores, retail pharmacies and online pharmacies), and regions (North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East and Africa)
Request For No-Obligation Table Of Content
https://www.factmr.com/connectus/sample?flag=T&rep_id=4717
Explore Fact.MR’s Coverage on the Healthcare Domain
Phototherapy Devices Market: Latest report by Fact.MR offers an exhaustive analysis on global phototherapy devices market on the opportunities, trends and challenges for the forecast period. The study analyzes crucial trends that are currently determining market growth. This report explicates on vital dynamics, such as the drivers, restraints, and opportunities for key market players along with key stakeholders and emerging players.
Acute Hepatic Porphyria (APH) Market: A detailed assessment of acute hepatic porphyria (APH) value chain analysis, business execution, and supply chain analysis across regional markets has been covered in the report. A list of prominent companies operating in the market along with their product portfolios enhances the reliability of this comprehensive research study.
Hormone Replacement Therapy Market: Fact.MR has published a detailed market insight on the global market for hormone replacement therapy market. A comprehensive estimate on eye socket implant market has been provided through an optimistic scenario as well as a conservative scenario, taking into account the detailed segmentation and exhaustive competitive landscape during the forecast period.
About Fact.MR
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.
Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E: sales@factmr.com
Market Intelligence Services: Marketngage.com
Source: Fact.MR
Erythropoietic Protoporphyria Treatment Reliant on Rising Cases of Porphyria: Study
Surge in demand for hormonal therapy and phototherapy to treat the new born and children by lowering the bilirubin levels in propelling the market growth
Fact.MR, Rockville MD: An ongoing market study by Fact.MR on global erythropoietic protoporphyria (EPP) treatment, evaluates a moderate growth for the upcoming decade. Owing to the technical advancements in the diagnostics and treatment of EPP.
According to Fact.MR, increasing demand for drug therapies such as antihistamine, hormonal therapy, phototherapy for EPP treatment to boost the demand through 2021 and beyond. Rising cases of erythropoietic protoporphyria in children is fueling the growth. First line hormonal therapies segment is expected to hold major market share until 2031.
For instance, according to a study by WHO, cases of porphyria were recorded approximately 5 cases per 100,000 person, among which majority of them were diagnosed in children. The prevalence for erythropoietic protoporphyria is recorded among 2% of the patients diagnosed with porphyria, for which the most common treatment is hormonal therapy approved by FDA.
“Significant demand of advanced EPP treatment therapeutics for EPP treatment and rising cases of enzyme deficiency among children is propelling the growth,” says the Fact.MR analyst.
Request a report sample to gain comprehensive insights at https://www.factmr.com/connectus/sample?flag=S&rep_id=4717
Key Takeaways
- US to remain in the spotlight owing to the emergence of novel treatment advancements
- Germany likely to emerge as the second most lucrative market owing to the rising cases of porphyria and treatment adoption
- China expected to lead the East Asia with the highest growth rate
- Owing to the poor healthcare infrastructure, GCC and rest of MEA expected to witness sluggish growth
- Hormonal therapy is likely to emerge as one of the most lucrative segment through 2021
- Retail and Hospital pharmacies is anticipated to emerge as highly sought after erythropoietic protoporphyria (EPP) treatment availability channel
Prominent Drivers
- Increasing cases of porphyria in children is surging the demand of antihistamines therapy to propel the growth
- Novel therapeutic development and technical advancement is driving the growth of EPP treatment market
Key Restraints
- Higher treatment cost and lack of healthcare facilities is posing a threat to the growth
Discover more about erythropoietic protoporphyria (EPP) treatment market with figures, data tables and the table of contents. You will also find detailed market segmentation on https://www.factmr.com/report/4717/erythropoietic-protoporphyria-epp-treatment-market
Competitive Landscape
Key PCR master mix manufacturers profiled by Fact.MR include Clinuvel Pharmaceuticals ALS, Johnson & Johnson, Tishcon Corp., Fenton Pharmaceuticals Ltd., In-Life Co., L’Oreal S.A, Pfizer Inc., Teva Pharmaceuticals, Sun Pharma Ltd., and Mylan N.V. others among others. As evaluated by Fact.MR, manufacturers are focusing on developing new model in order to sustain and recover after the pandemic outbreak.
In 2020, a clinical trial was conducted in collaboration with researchers at Karolinska Institute in Sweden now shows that a new drug candidate can prevent attacks in the patients with acute porphyria.
Also, in March 2020, Alnylam announced approval of GIVLAARI® (givosiran) in the European Union for the treatment of acute hepatic porphyria (AHP) in adults and adolescents.
More Insights on the Erythropoietic Protoporphyria (EPP) Treatment Market
Fact.MR recent study offers an unbiased analysis on global erythropoietic protoporphyria (EPP) treatment market. In order to understand the global market potential, its growth, and opportunities, the market is segmented on the basis of therapy (hormonal therapy, adjunctive therapies, and phototherapy), distribution channels (hospital pharmacies, drug stores, retail pharmacies and online pharmacies), and regions (North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East and Africa)
Request For No-Obligation Table Of Content
https://www.factmr.com/connectus/sample?flag=T&rep_id=4717
Explore Fact.MR’s Coverage on the Healthcare Domain
Phototherapy Devices Market: Latest report by Fact.MR offers an exhaustive analysis on global phototherapy devices market on the opportunities, trends and challenges for the forecast period. The study analyzes crucial trends that are currently determining market growth. This report explicates on vital dynamics, such as the drivers, restraints, and opportunities for key market players along with key stakeholders and emerging players.
Acute Hepatic Porphyria (APH) Market: A detailed assessment of acute hepatic porphyria (APH) value chain analysis, business execution, and supply chain analysis across regional markets has been covered in the report. A list of prominent companies operating in the market along with their product portfolios enhances the reliability of this comprehensive research study.
Hormone Replacement Therapy Market: Fact.MR has published a detailed market insight on the global market for hormone replacement therapy market. A comprehensive estimate on eye socket implant market has been provided through an optimistic scenario as well as a conservative scenario, taking into account the detailed segmentation and exhaustive competitive landscape during the forecast period.
About Fact.MR
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.
Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E: sales@factmr.com
Market Intelligence Services: Marketngage.com
Source: Fact.MR
Erythropoietic Protoporphyria Treatment Reliant on Rising Cases of Porphyria: Study
Surge in demand for hormonal therapy and phototherapy to treat the new born and children by lowering the bilirubin levels in propelling the market growth
Fact.MR, Rockville MD: An ongoing market study by Fact.MR on global erythropoietic protoporphyria (EPP) treatment, evaluates a moderate growth for the upcoming decade. Owing to the technical advancements in the diagnostics and treatment of EPP.
According to Fact.MR, increasing demand for drug therapies such as antihistamine, hormonal therapy, phototherapy for EPP treatment to boost the demand through 2021 and beyond. Rising cases of erythropoietic protoporphyria in children is fueling the growth. First line hormonal therapies segment is expected to hold major market share until 2031.
For instance, according to a study by WHO, cases of porphyria were recorded approximately 5 cases per 100,000 person, among which majority of them were diagnosed in children. The prevalence for erythropoietic protoporphyria is recorded among 2% of the patients diagnosed with porphyria, for which the most common treatment is hormonal therapy approved by FDA.
“Significant demand of advanced EPP treatment therapeutics for EPP treatment and rising cases of enzyme deficiency among children is propelling the growth,” says the Fact.MR analyst.
Request a report sample to gain comprehensive insights at https://www.factmr.com/connectus/sample?flag=S&rep_id=4717
Key Takeaways
- US to remain in the spotlight owing to the emergence of novel treatment advancements
- Germany likely to emerge as the second most lucrative market owing to the rising cases of porphyria and treatment adoption
- China expected to lead the East Asia with the highest growth rate
- Owing to the poor healthcare infrastructure, GCC and rest of MEA expected to witness sluggish growth
- Hormonal therapy is likely to emerge as one of the most lucrative segment through 2021
- Retail and Hospital pharmacies is anticipated to emerge as highly sought after erythropoietic protoporphyria (EPP) treatment availability channel
Prominent Drivers
- Increasing cases of porphyria in children is surging the demand of antihistamines therapy to propel the growth
- Novel therapeutic development and technical advancement is driving the growth of EPP treatment market
Key Restraints
- Higher treatment cost and lack of healthcare facilities is posing a threat to the growth
Discover more about erythropoietic protoporphyria (EPP) treatment market with figures, data tables and the table of contents. You will also find detailed market segmentation on https://www.factmr.com/report/4717/erythropoietic-protoporphyria-epp-treatment-market
Competitive Landscape
Key PCR master mix manufacturers profiled by Fact.MR include Clinuvel Pharmaceuticals ALS, Johnson & Johnson, Tishcon Corp., Fenton Pharmaceuticals Ltd., In-Life Co., L’Oreal S.A, Pfizer Inc., Teva Pharmaceuticals, Sun Pharma Ltd., and Mylan N.V. others among others. As evaluated by Fact.MR, manufacturers are focusing on developing new model in order to sustain and recover after the pandemic outbreak.
In 2020, a clinical trial was conducted in collaboration with researchers at Karolinska Institute in Sweden now shows that a new drug candidate can prevent attacks in the patients with acute porphyria.
Also, in March 2020, Alnylam announced approval of GIVLAARI® (givosiran) in the European Union for the treatment of acute hepatic porphyria (AHP) in adults and adolescents.
More Insights on the Erythropoietic Protoporphyria (EPP) Treatment Market
Fact.MR recent study offers an unbiased analysis on global erythropoietic protoporphyria (EPP) treatment market. In order to understand the global market potential, its growth, and opportunities, the market is segmented on the basis of therapy (hormonal therapy, adjunctive therapies, and phototherapy), distribution channels (hospital pharmacies, drug stores, retail pharmacies and online pharmacies), and regions (North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East and Africa)
Request For No-Obligation Table Of Content
https://www.factmr.com/connectus/sample?flag=T&rep_id=4717
Explore Fact.MR’s Coverage on the Healthcare Domain
Phototherapy Devices Market: Latest report by Fact.MR offers an exhaustive analysis on global phototherapy devices market on the opportunities, trends and challenges for the forecast period. The study analyzes crucial trends that are currently determining market growth. This report explicates on vital dynamics, such as the drivers, restraints, and opportunities for key market players along with key stakeholders and emerging players.
Acute Hepatic Porphyria (APH) Market: A detailed assessment of acute hepatic porphyria (APH) value chain analysis, business execution, and supply chain analysis across regional markets has been covered in the report. A list of prominent companies operating in the market along with their product portfolios enhances the reliability of this comprehensive research study.
Hormone Replacement Therapy Market: Fact.MR has published a detailed market insight on the global market for hormone replacement therapy market. A comprehensive estimate on eye socket implant market has been provided through an optimistic scenario as well as a conservative scenario, taking into account the detailed segmentation and exhaustive competitive landscape during the forecast period.
About Fact.MR
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.
Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E: sales@factmr.com
Market Intelligence Services: Marketngage.com
Source: Fact.MR
Erythropoietic Protoporphyria Treatment Reliant on Rising Cases of Porphyria: Study
Surge in demand for hormonal therapy and phototherapy to treat the new born and children by lowering the bilirubin levels in propelling the market growth
Fact.MR, Rockville MD: An ongoing market study by Fact.MR on global erythropoietic protoporphyria (EPP) treatment, evaluates a moderate growth for the upcoming decade. Owing to the technical advancements in the diagnostics and treatment of EPP.
According to Fact.MR, increasing demand for drug therapies such as antihistamine, hormonal therapy, phototherapy for EPP treatment to boost the demand through 2021 and beyond. Rising cases of erythropoietic protoporphyria in children is fueling the growth. First line hormonal therapies segment is expected to hold major market share until 2031.
For instance, according to a study by WHO, cases of porphyria were recorded approximately 5 cases per 100,000 person, among which majority of them were diagnosed in children. The prevalence for erythropoietic protoporphyria is recorded among 2% of the patients diagnosed with porphyria, for which the most common treatment is hormonal therapy approved by FDA.
“Significant demand of advanced EPP treatment therapeutics for EPP treatment and rising cases of enzyme deficiency among children is propelling the growth,” says the Fact.MR analyst.
Request a report sample to gain comprehensive insights at https://www.factmr.com/connectus/sample?flag=S&rep_id=4717
Key Takeaways
- US to remain in the spotlight owing to the emergence of novel treatment advancements
- Germany likely to emerge as the second most lucrative market owing to the rising cases of porphyria and treatment adoption
- China expected to lead the East Asia with the highest growth rate
- Owing to the poor healthcare infrastructure, GCC and rest of MEA expected to witness sluggish growth
- Hormonal therapy is likely to emerge as one of the most lucrative segment through 2021
- Retail and Hospital pharmacies is anticipated to emerge as highly sought after erythropoietic protoporphyria (EPP) treatment availability channel
Prominent Drivers
- Increasing cases of porphyria in children is surging the demand of antihistamines therapy to propel the growth
- Novel therapeutic development and technical advancement is driving the growth of EPP treatment market
Key Restraints
- Higher treatment cost and lack of healthcare facilities is posing a threat to the growth
Discover more about erythropoietic protoporphyria (EPP) treatment market with figures, data tables and the table of contents. You will also find detailed market segmentation on https://www.factmr.com/report/4717/erythropoietic-protoporphyria-epp-treatment-market
Competitive Landscape
Key PCR master mix manufacturers profiled by Fact.MR include Clinuvel Pharmaceuticals ALS, Johnson & Johnson, Tishcon Corp., Fenton Pharmaceuticals Ltd., In-Life Co., L’Oreal S.A, Pfizer Inc., Teva Pharmaceuticals, Sun Pharma Ltd., and Mylan N.V. others among others. As evaluated by Fact.MR, manufacturers are focusing on developing new model in order to sustain and recover after the pandemic outbreak.
In 2020, a clinical trial was conducted in collaboration with researchers at Karolinska Institute in Sweden now shows that a new drug candidate can prevent attacks in the patients with acute porphyria.
Also, in March 2020, Alnylam announced approval of GIVLAARI® (givosiran) in the European Union for the treatment of acute hepatic porphyria (AHP) in adults and adolescents.
More Insights on the Erythropoietic Protoporphyria (EPP) Treatment Market
Fact.MR recent study offers an unbiased analysis on global erythropoietic protoporphyria (EPP) treatment market. In order to understand the global market potential, its growth, and opportunities, the market is segmented on the basis of therapy (hormonal therapy, adjunctive therapies, and phototherapy), distribution channels (hospital pharmacies, drug stores, retail pharmacies and online pharmacies), and regions (North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East and Africa)
Request For No-Obligation Table Of Content
https://www.factmr.com/connectus/sample?flag=T&rep_id=4717
Explore Fact.MR’s Coverage on the Healthcare Domain
Phototherapy Devices Market: Latest report by Fact.MR offers an exhaustive analysis on global phototherapy devices market on the opportunities, trends and challenges for the forecast period. The study analyzes crucial trends that are currently determining market growth. This report explicates on vital dynamics, such as the drivers, restraints, and opportunities for key market players along with key stakeholders and emerging players.
Acute Hepatic Porphyria (APH) Market: A detailed assessment of acute hepatic porphyria (APH) value chain analysis, business execution, and supply chain analysis across regional markets has been covered in the report. A list of prominent companies operating in the market along with their product portfolios enhances the reliability of this comprehensive research study.
Hormone Replacement Therapy Market: Fact.MR has published a detailed market insight on the global market for hormone replacement therapy market. A comprehensive estimate on eye socket implant market has been provided through an optimistic scenario as well as a conservative scenario, taking into account the detailed segmentation and exhaustive competitive landscape during the forecast period.
About Fact.MR
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.
Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E: sales@factmr.com
Market Intelligence Services: Marketngage.com
Source: Fact.MR
Erythropoietic Protoporphyria Treatment Reliant on Rising Cases of Porphyria: Study
Surge in demand for hormonal therapy and phototherapy to treat the new born and children by lowering the bilirubin levels in propelling the market growth
Fact.MR, Rockville MD: An ongoing market study by Fact.MR on global erythropoietic protoporphyria (EPP) treatment, evaluates a moderate growth for the upcoming decade. Owing to the technical advancements in the diagnostics and treatment of EPP.
According to Fact.MR, increasing demand for drug therapies such as antihistamine, hormonal therapy, phototherapy for EPP treatment to boost the demand through 2021 and beyond. Rising cases of erythropoietic protoporphyria in children is fueling the growth. First line hormonal therapies segment is expected to hold major market share until 2031.
For instance, according to a study by WHO, cases of porphyria were recorded approximately 5 cases per 100,000 person, among which majority of them were diagnosed in children. The prevalence for erythropoietic protoporphyria is recorded among 2% of the patients diagnosed with porphyria, for which the most common treatment is hormonal therapy approved by FDA.
“Significant demand of advanced EPP treatment therapeutics for EPP treatment and rising cases of enzyme deficiency among children is propelling the growth,” says the Fact.MR analyst.
Request a report sample to gain comprehensive insights at https://www.factmr.com/connectus/sample?flag=S&rep_id=4717
Key Takeaways
- US to remain in the spotlight owing to the emergence of novel treatment advancements
- Germany likely to emerge as the second most lucrative market owing to the rising cases of porphyria and treatment adoption
- China expected to lead the East Asia with the highest growth rate
- Owing to the poor healthcare infrastructure, GCC and rest of MEA expected to witness sluggish growth
- Hormonal therapy is likely to emerge as one of the most lucrative segment through 2021
- Retail and Hospital pharmacies is anticipated to emerge as highly sought after erythropoietic protoporphyria (EPP) treatment availability channel
Prominent Drivers
- Increasing cases of porphyria in children is surging the demand of antihistamines therapy to propel the growth
- Novel therapeutic development and technical advancement is driving the growth of EPP treatment market
Key Restraints
- Higher treatment cost and lack of healthcare facilities is posing a threat to the growth
Discover more about erythropoietic protoporphyria (EPP) treatment market with figures, data tables and the table of contents. You will also find detailed market segmentation on https://www.factmr.com/report/4717/erythropoietic-protoporphyria-epp-treatment-market
Competitive Landscape
Key PCR master mix manufacturers profiled by Fact.MR include Clinuvel Pharmaceuticals ALS, Johnson & Johnson, Tishcon Corp., Fenton Pharmaceuticals Ltd., In-Life Co., L’Oreal S.A, Pfizer Inc., Teva Pharmaceuticals, Sun Pharma Ltd., and Mylan N.V. others among others. As evaluated by Fact.MR, manufacturers are focusing on developing new model in order to sustain and recover after the pandemic outbreak.
In 2020, a clinical trial was conducted in collaboration with researchers at Karolinska Institute in Sweden now shows that a new drug candidate can prevent attacks in the patients with acute porphyria.
Also, in March 2020, Alnylam announced approval of GIVLAARI® (givosiran) in the European Union for the treatment of acute hepatic porphyria (AHP) in adults and adolescents.
More Insights on the Erythropoietic Protoporphyria (EPP) Treatment Market
Fact.MR recent study offers an unbiased analysis on global erythropoietic protoporphyria (EPP) treatment market. In order to understand the global market potential, its growth, and opportunities, the market is segmented on the basis of therapy (hormonal therapy, adjunctive therapies, and phototherapy), distribution channels (hospital pharmacies, drug stores, retail pharmacies and online pharmacies), and regions (North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East and Africa)
Request For No-Obligation Table Of Content
https://www.factmr.com/connectus/sample?flag=T&rep_id=4717
Explore Fact.MR’s Coverage on the Healthcare Domain
Phototherapy Devices Market: Latest report by Fact.MR offers an exhaustive analysis on global phototherapy devices market on the opportunities, trends and challenges for the forecast period. The study analyzes crucial trends that are currently determining market growth. This report explicates on vital dynamics, such as the drivers, restraints, and opportunities for key market players along with key stakeholders and emerging players.
Acute Hepatic Porphyria (APH) Market: A detailed assessment of acute hepatic porphyria (APH) value chain analysis, business execution, and supply chain analysis across regional markets has been covered in the report. A list of prominent companies operating in the market along with their product portfolios enhances the reliability of this comprehensive research study.
Hormone Replacement Therapy Market: Fact.MR has published a detailed market insight on the global market for hormone replacement therapy market. A comprehensive estimate on eye socket implant market has been provided through an optimistic scenario as well as a conservative scenario, taking into account the detailed segmentation and exhaustive competitive landscape during the forecast period.
About Fact.MR
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.
Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E: sales@factmr.com
Follow Us: LinkedIn | Twitter
Market Intelligence Services: Marketngage.com
Source: Fact.MR